Contineum Therapeutics (NASDAQ:CTNM) Now Covered by Robert W. Baird

Investment analysts at Robert W. Baird assumed coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $32.00 price target on the stock. Robert W. Baird’s price objective would suggest a potential upside of 96.80% from the stock’s current price.

Separately, Royal Bank of Canada boosted their price target on Contineum Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, August 14th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $29.50.

Contineum Therapeutics Trading Down 0.1 %

NASDAQ CTNM opened at $16.26 on Tuesday. Contineum Therapeutics has a 12 month low of $13.27 and a 12 month high of $22.00. The company’s fifty day moving average price is $17.98 and its two-hundred day moving average price is $17.64.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02). Analysts predict that Contineum Therapeutics will post -2.04 EPS for the current year.

Hedge Funds Weigh In On Contineum Therapeutics

A number of large investors have recently bought and sold shares of the business. Johnson & Johnson acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter worth approximately $34,853,000. Perceptive Advisors LLC acquired a new stake in Contineum Therapeutics in the second quarter worth $27,589,000. Versant Venture Management LLC bought a new stake in Contineum Therapeutics in the second quarter valued at $16,169,000. Squarepoint Ops LLC acquired a new position in shares of Contineum Therapeutics during the second quarter valued at $2,642,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Contineum Therapeutics during the second quarter worth about $1,174,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).